Lee, Hyojin Lee, Dongjin Park, Jea Ho Song, Sang Hoon Jeong, In Gab Kim, Choung-Soo Searson, Peter C. Lee, Kwan Hyi 2024-01-20T01:01:36Z 2024-01-20T01:01:36Z 2021-09-05 2017-08 0142-9612 https://pubs.kist.re.kr/handle/201004/122468 Identifying genetic diversity is important for studies in cancer as it can provide insights on disease progression and treatment. Although clinical outcome and major symptom of cancer might be same in all patients, the type of overexpressed gene could be different. Even though prostate-specific antigen assay is a good tool widely used for prostate cancer diagnosis, it is not capable of providing information on genetic differences. Therefore, screening method that can differentiate genetic differences is necessary. Here we detected different types of TMPRSS2-ERG, prostate cancer specific fusion genes, to verify the genetic diversity between the patients using high throughput screening method, bio-barcode assay. Prostate cancer patients with different types of fusion gene were successfully differentiated directly from untreated patients' urine, while traditional PSA assay could not. This non-invasive assay, when used with PSA assay, can be a strong secondary screening method which can offer new insights on disease progression and clinical outcome. (C) 2017 Elsevier Ltd. All rights reserved. English ELSEVIER SCI LTD BIO-BARCODE ASSAY SENSITIVE DETECTION BIOMARKERS PROTEIN PCR TRANSISTOR EXPRESSION DIAGNOSIS STATEMENT IMPROVE High throughput differential identification of TMPRSS2-ERG fusion genes in prostate cancer patient urine Article 10.1016/j.biomaterials.2017.04.049 1 BIOMATERIALS, v.135, pp.23 - 29 BIOMATERIALS 135 23 29 scie scopus 000401718000003 2-s2.0-85018278452 Engineering, Biomedical Materials Science, Biomaterials Engineering Materials Science Article BIO-BARCODE ASSAY SENSITIVE DETECTION BIOMARKERS PROTEIN PCR TRANSISTOR EXPRESSION DIAGNOSIS STATEMENT IMPROVE Fusion gene Bio-barcode assay TMPRSS2-ERG Prostate cancer Urine detection Non-invasive